Every material Form 8-K Kairos Pharma, LTD. has filed with the SEC since October 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Kairos Pharma announced it was named a winner of the 2026 Biotech Breakthrough Awards in the Cancer Immunology Solution of the Year category for its ENV-105 (carotuximab) work in metastatic prostate cancer and non-small cell lung cancer. The filing reports no financial results, guidance, or transaction, so the award itself does not change reported financial figures.
Award: Cancer Immunology Solution of the Year, 2026 Biotech Breakthrough Awards
Lead candidate ENV-105 (carotuximab) is in development for metastatic prostate cancer and non-small cell lung cancer
Press release references earlier positive interim Phase 2 efficacy data for ENV-105 with apalutamide in metastatic castration-resistant prostate cancer
Press release dated November 5, 2026, furnished as Exhibit 99.1
Kairos Pharma amended its equity line of credit purchase agreement with Helena Global Investment Opportunities I Ltd. three times in 2026, changing the purchase price, the pricing period and the period during which the company can use the facility. The company also furnished materials for a November 3, 2026 conference presentation on interim efficacy data for ENV-105. The filing does not state the number of shares or the proceeds involved, but the amendments change the terms under which shares can be sold to Helena, which matters to shareholders.
February 4, 2026: purchase price set at 97% of the average daily VWAP during the Pricing Period.
October 26, 2026: Pricing Period shortened from three Trading Days to one Trading Day.
October 29, 2026: option to use the equity line extended one year to December 31, 2028.
November 3, 2026: President and Chief Scientific Officer Neil Bhowmick presents interim ENV-105 data; median progression-free survival was 17.7 months with the combination versus 2 months with apalutamide alone (P=0.0008).
Kairos Pharma said interim Phase 2 data showed a statistically significant difference in progression-free survival for patients treated with ENV-105 plus apalutamide compared with apalutamide alone. The company also modified the trial protocol to enroll patients earlier in disease progression, with completion targeted in or before the fourth quarter of 2027.
Median progression-free survival was 17.7 months with ENV-105 plus apalutamide versus 2 months with apalutamide alone (P=0.0008).
The modified protocol enrolls patients after a PSA increase following upfront androgen signaling inhibitor treatment, randomized to enzalutamide alone or with ENV-105.
Kairos Pharma targets completing the Phase 2 trial in or before the fourth quarter of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Kairos Pharma, LTD. filing is on SEC EDGAR ↗. 8-K briefs of other companies →